Results from preclinical studies suggest that isoform-targeted inhibition of macrophage GSK3α or GSK3β may be effective in the treatment of acute myeloid leukemia [78] and atherosclerosis [40,43]. The gene discussed is GSK3A; the disease is acute myeloid leukemia.